Skip to content
The Nexus
DossierENTITY

Dr. Anna Durbin

Coverage of Dr. Anna Durbin in the Nexus archive.

Earliest in view: Jun 18 · 20:11 UTCMost recent: Aug 13 · 10:24 UTC
Co-mentioned in this coverage
Recent coverage
  • HEALTHAug 13 · 10:24 UTCWPLG LOCAL 10 MIAMI
    Trump's vaccine plan would require millions of individual shots last used decades ago

    An executive order from President Donald Trump calls for separating combination shots, such as the measles, mumps, and rubella vaccine, into individual injections, requiring drugmakers to revive vaccines unused in decades. Public health experts criticize this plan, stating there is no scientific basis for the change, noting that implementing it would require pharmaceutical companies to conduct large studies and overhaul manufacturing facilities.

  • HEALTHAug 13 · 10:24 UTCWDIV CLICKONDETROIT
    Trump's vaccine plan would require millions of individual shots last used decades ago

    A plan proposed by Donald Trump calls for separating combination vaccines, such as MMR, into individual shots and spacing out vaccinations, which would require drugmakers to revive unused vaccine formulations and build new manufacturing plants. Public health experts argue that this policy lacks scientific basis and would impose significant financial and logistical challenges on parents and providers. Implementing the changes could take years and involve massive research and development by pharmaceutical companies.

  • HEALTHJun 18 · 20:11 UTCWPLG LOCAL 10 MIAMI
    FDA panel backs first-of-its-kind flu vaccine using mRNA technology

    An FDA panel recommended approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, citing its benefits outweighing risks. The vaccine, developed using technology similar to COVID-19 vaccines, showed a 27% reduction in flu cases compared to traditional vaccines in clinical trials and is under final FDA review for potential approval by August.